Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 22;12:641206. doi: 10.3389/fimmu.2021.641206

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 He, Hung, Liang, Zhang, Gao, Chu, Zhang, Xu, Chung and Wang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Effects of Sunitinib on endometriosis lesions. (A) Changes to body weights during control and Sunitinib treatment. (B) Size of the endometriotic lesions after 1 and 3 weeks of treatment. (C) Weight of the endometriotic lesions after 1 and 3 weeks of treatment. Data are expressed as the mean ± SEM from 10 animals in each group, *p < 0.05. (D) Representative histology sections of the endometriotic lesions from control and Sunitinib groups. D1: endometriotic lesion after 1 week of control treatment; D2: endometriotic lesion after 1 week of Sunitinib treatment; D3: endometriotic lesion after 3 weeks of control treatment; D4: endometriotic lesion after 3 weeks of Sunitinib treatment, Scale bar: 200μm.